{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:20:07Z","timestamp":1788369607284,"version":"build-2803163510"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,28]]},"DOI":"10.7759\/cureus.20776","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T14:06:37Z","timestamp":1640700397000},"source":"Crossref","is-referenced-by-count":7,"title":["Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD)"],"prefix":"10.7759","author":[{"given":"Madhangi","family":"Parameswaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamzah A","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jafor","family":"Sadeque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharan","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaithanya","family":"Avanthika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abimbola  E","family":"Arisoyin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maulik B","family":"Dhanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swaroopa M","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani N","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012, 55:2005-23. 10.1002\/hep.25762","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-121808-102132","article-title":"Nonalcoholic fatty liver disease: pathology and pathogenesis","volume":"5","author":"Tiniakos DG","year":"2010","unstructured":"Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010, 5:145-71. 10.1146\/annurev-pathol-121808-102132","journal-title":"Annu Rev Pathol"},{"key":"ref3","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig J","year":"1980","unstructured":"Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980, 55:434-8.","journal-title":"Mayo Clin Proc"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2017.08.003","article-title":"The natural history of nonalcoholic fatty liver disease\u2014an evolving view","volume":"22","author":"Lindenmeyer CC","year":"2018","unstructured":"Lindenmeyer CC, McCullough AJ. The natural history of nonalcoholic fatty liver disease\u2014an evolving view. Clin Liver Dis. 2018, 22:11-21. 10.1016\/j.cld.2017.08.003","journal-title":"Clin Liver Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i27.2974","article-title":"Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from \"two hit theory\" to \"multiple hit model\"","volume":"24","author":"Fang YL","year":"2018","unstructured":"Fang YL, Chen H, Wang CL, Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from \"two hit theory\" to \"multiple hit model\". World J Gastroenterol. 2018, 24:2974-83. 10.3748\/wjg.v24.i27.2974","journal-title":"World J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2010.547869","article-title":"Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment","volume":"44","author":"Alisi A","year":"2012","unstructured":"Alisi A, Cianfarani S, Manco M, Agostoni C, Nobili V. Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. Ann Med. 2012, 44:29-40. 10.3109\/07853890.2010.547869","journal-title":"Ann Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e318252a13f","article-title":"Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee","volume":"54","author":"Vajro P","year":"2012","unstructured":"Vajro P, Lenta S, Socha P, et al.. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr. 2012, 54:700-13. 10.1097\/MPG.0b013e318252a13f","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.B0720016","article-title":"Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease","volume":"9","author":"Chen ZW","year":"2008","unstructured":"Chen ZW, Chen LY, Dai HL, Chen JH, Fang LZ. Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J Zhejiang Univ Sci B. 2008, 9:616-22. 10.1631\/jzus.B0720016","journal-title":"J Zhejiang Univ Sci B"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000168638.84840.ff","article-title":"The epidemiology of nonalcoholic fatty liver disease in adults","volume":"40","author":"Clark JM","year":"2006","unstructured":"Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006, 40:S5-10. 10.1097\/01.mcg.0000168638.84840.ff","journal-title":"J Clin Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.183","article-title":"NAFLD, NASH and liver cancer","volume":"10","author":"Michelotti GA","year":"2013","unstructured":"Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013, 10:656-65. 10.1038\/nrgastro.2013.183","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi ZM","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016, 64:73-84. 10.1002\/hep.28431","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong RJ","year":"2015","unstructured":"Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015, 148:547-55. 10.1053\/j.gastro.2014.11.039","journal-title":"Gastroenterology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i29.3377","article-title":"Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence","volume":"17","author":"Zelber-Sagi S","year":"2011","unstructured":"Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol. 2011, 17:3377-89. 10.3748\/wjg.v17.i29.3377","journal-title":"World J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.11-2-176","article-title":"Non-alcoholic fatty liver disease: a massive problem","volume":"11","author":"Day CP","year":"2011","unstructured":"Day CP. Non-alcoholic fatty liver disease: a massive problem. Clin Med (Lond). 2011, 11:176-8. 10.7861\/clinmedicine.11-2-176","journal-title":"Clin Med (Lond)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2011.117","article-title":"Nonalcoholic fatty liver disease: targeted therapy in children--what is the right way?","volume":"8","author":"Alisi A","year":"2011","unstructured":"Alisi A, Nobili V. Nonalcoholic fatty liver disease: targeted therapy in children--what is the right way?. Nat Rev Gastroenterol Hepatol. 2011, 8:425-6. 10.1038\/nrgastro.2011.117","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-018-2947-0","article-title":"Molecular pathways of nonalcoholic fatty liver disease development and progression","volume":"76","author":"Bessone F","year":"2019","unstructured":"Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019, 76:99-128. 10.1007\/s00018-018-2947-0","journal-title":"Cell Mol Life Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2017.01.147","article-title":"AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions","volume":"49","author":"Italian Association for the Study of the Liver (AISF)","year":"2017","unstructured":"Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. Dig Liver Dis. 2017, 49:471-83. 10.1016\/j.dld.2017.01.147","journal-title":"Dig Liver Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti E","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016, 65:1038-48. 10.1016\/j.metabol.2015.12.012","journal-title":"Metabolism"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms15058591","article-title":"Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation","volume":"15","author":"Peverill W","year":"2014","unstructured":"Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci. 2014, 15:8591-638. 10.3390\/ijms15058591","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.06.021","article-title":"Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C","volume":"54","author":"Garc\u00eda-Monz\u00f3n C","year":"2011","unstructured":"Garc\u00eda-Monz\u00f3n C, Lo Iacono O, Mayoral R, et al.. Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C. J Hepatol. 2011, 54:142-52. 10.1016\/j.jhep.2010.06.021","journal-title":"J Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(03)00907-7","article-title":"Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis","volume":"125","author":"Feldstein AE","year":"2003","unstructured":"Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003, 125:437-43. 10.1016\/s0016-5085(03)00907-7","journal-title":"Gastroenterology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2015.03.029","article-title":"Role of hepatocyte S6K1 in palmitic acid-induced endoplasmic reticulum stress, lipotoxicity, insulin resistance and in oleic acid-induced protection","volume":"80","author":"Pardo V","year":"2015","unstructured":"Pardo V, Gonz\u00e1lez-Rodr\u00edguez \u00c1, Muntan\u00e9 J, Kozma SC, Valverde \u00c1M. Role of hepatocyte S6K1 in palmitic acid-induced endoplasmic reticulum stress, lipotoxicity, insulin resistance and in oleic acid-induced protection. Food Chem Toxicol. 2015, 80:298-309. 10.1016\/j.fct.2015.03.029","journal-title":"Food Chem Toxicol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options","volume":"1","author":"Gastaldelli A","year":"2019","unstructured":"Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep. 2019, 1:312-28. 10.1016\/j.jhepr.2019.07.002","journal-title":"JHEP Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00015.2017","article-title":"Interorgan metabolic crosstalk in human insulin resistance","volume":"98","author":"Gancheva S","year":"2018","unstructured":"Gancheva S, Jelenik T, \u00c1lvarez-Hern\u00e1ndez E, Roden M. Interorgan metabolic crosstalk in human insulin resistance. Physiol Rev. 2018, 98:1371-415. 10.1152\/physrev.00015.2017","journal-title":"Physiol Rev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000080","article-title":"Fatty acid sources and their fluxes as they contribute to plasma triglyceride concentrations and fatty liver in humans","volume":"25","author":"Jacome-Sosa MM","year":"2014","unstructured":"Jacome-Sosa MM, Parks EJ. Fatty acid sources and their fluxes as they contribute to plasma triglyceride concentrations and fatty liver in humans. Curr Opin Lipidol. 2014, 25:213-20. 10.1097\/MOL.0000000000000080","journal-title":"Curr Opin Lipidol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.147","article-title":"NAFLD and diabetes mellitus","volume":"14","author":"Tilg H","year":"2017","unstructured":"Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017, 14:32-42. 10.1038\/nrgastro.2016.147","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases","volume":"27","author":"Samuel VT","year":"2018","unstructured":"Samuel VT, Shulman GI. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metab. 2018, 27:22-41. 10.1016\/j.cmet.2017.08.002","journal-title":"Cell Metab"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman SL","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018, 24:908-22. 10.1038\/s41591-018-0104-9","journal-title":"Nat Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25772","article-title":"Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis","volume":"56","author":"Loomba R","year":"2012","unstructured":"Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012, 56:943-51. 10.1002\/hep.25772","journal-title":"Hepatology"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1126\/science.1160794","article-title":"A stress signaling pathway in adipose tissue regulates hepatic insulin resistance","volume":"322","author":"Sabio G","year":"2008","unstructured":"Sabio G, Das M, Mora A, et al.. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science. 2008, 322:1539-43. 10.1126\/science.1160794","journal-title":"Science"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1159\/000282083","article-title":"The role of cytokines in non-alcoholic fatty liver disease","volume":"28","author":"Tilg H","year":"2010","unstructured":"Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis. 2010, 28:179-85. 10.1159\/000282083","journal-title":"Dig Dis"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/nature26138","article-title":"Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance","volume":"555","author":"Ghorpade DS","year":"2018","unstructured":"Ghorpade DS, Ozcan L, Zheng Z, et al.. Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. Nature. 2018, 555:673-7. 10.1038\/nature26138","journal-title":"Nature"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1126\/science.1103160","article-title":"Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes","volume":"306","author":"Ozcan U","year":"2004","unstructured":"Ozcan U, Cao Q, Yilmaz E, et al.. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004, 306:457-61. 10.1126\/science.1103160","journal-title":"Science"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2020.02.025","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"152","author":"Chen Z","year":"2020","unstructured":"Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 2020, 152:116-41. 10.1016\/j.freeradbiomed.2020.02.025","journal-title":"Free Radic Biol Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90281-2","article-title":"Oxidative stress: from basic research to clinical application","volume":"91","author":"Sies H","year":"1991","unstructured":"Sies H. Oxidative stress: from basic research to clinical application. Am J Med. 1991, 91:S31-8. 10.1016\/0002-9343(91)90281-2","journal-title":"Am J Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2016.11.006","article-title":"Mitochondrial adaptation in nonalcoholic fatty liver disease: novel mechanisms and treatment strategies","volume":"28","author":"Sunny NE","year":"2017","unstructured":"Sunny NE, Bril F, Cusi K. Mitochondrial adaptation in nonalcoholic fatty liver disease: novel mechanisms and treatment strategies. Trends Endocrinol Metab. 2017, 28:250-60. 10.1016\/j.tem.2016.11.006","journal-title":"Trends Endocrinol Metab"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55020026","article-title":"Oxidative stress and antioxidant biomarkers in clinical and experimental models of non-alcoholic fatty liver disease","volume":"55","author":"Ore A","year":"2019","unstructured":"Ore A, Akinloye OA. Oxidative stress and antioxidant biomarkers in clinical and experimental models of non-alcoholic fatty liver disease. Medicina (Kaunas). 2019, 55:26. 10.3390\/medicina55020026","journal-title":"Medicina (Kaunas)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20021121","article-title":"Complex I-mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)+ oxidation-reduction state","volume":"368","author":"Kushnareva Y","year":"2002","unstructured":"Kushnareva Y, Murphy AN, Andreyev A. Complex I-mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)+ oxidation-reduction state. Biochem J. 2002, 368:545-53. 10.1042\/BJ20021121","journal-title":"Biochem J"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2016.6776","article-title":"Oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis","volume":"26","author":"Spahis S","year":"2017","unstructured":"Spahis S, Delvin E, Borys JM, Levy E. Oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis. Antioxid Redox Signal. 2017, 26:519-41. 10.1089\/ars.2016.6776","journal-title":"Antioxid Redox Signal"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-019-01178-1","article-title":"Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease","volume":"42","author":"Lee J","year":"2019","unstructured":"Lee J, Park JS, Roh YS. Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease. Arch Pharm Res. 2019, 42:935-46. 10.1007\/s12272-019-01178-1","journal-title":"Arch Pharm Res"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.02.026","article-title":"Targeting hepatic macrophages to treat liver diseases","volume":"66","author":"Tacke F","year":"2017","unstructured":"Tacke F. Targeting hepatic macrophages to treat liver diseases. J Hepatol. 2017, 66:1300-12. 10.1016\/j.jhep.2017.02.026","journal-title":"J Hepatol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12537","article-title":"Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis","volume":"34","author":"Csak T","year":"2014","unstructured":"Csak T, Pillai A, Ganz M, et al.. Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis. Liver Int. 2014, 34:1402-13. 10.1111\/liv.12537","journal-title":"Liver Int"},{"key":"ref44","article-title":"Macrophages in nonalcoholic steatohepatitis: friend or foe?","volume":"6","author":"Grunhut J","year":"2018","unstructured":"Grunhut J, Wang W, Aykut B, Gakhal I, Torres-Hernandez A, Miller G. Macrophages in nonalcoholic steatohepatitis: friend or foe?. Eur Med J Hepatol. 2018, 6:100-109.","journal-title":"Eur Med J Hepatol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i42.15532","article-title":"Liver transplantation and non-alcoholic fatty liver disease","volume":"20","author":"Zezos P","year":"2014","unstructured":"Zezos P, Renner EL. Liver transplantation and non-alcoholic fatty liver disease. World J Gastroenterol. 2014, 20:15532-8. 10.3748\/wjg.v20.i42.15532","journal-title":"World J Gastroenterol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0000000000000502","article-title":"Nonalcoholic steatohepatitis: the new frontier for liver transplantation","volume":"23","author":"Bzowej NH","year":"2018","unstructured":"Bzowej NH. Nonalcoholic steatohepatitis: the new frontier for liver transplantation. Curr Opin Organ Transplant. 2018, 23:169-74. 10.1097\/MOT.0000000000000502","journal-title":"Curr Opin Organ Transplant"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23594","article-title":"Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection","volume":"51","author":"Starley BQ","year":"2010","unstructured":"Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010, 51:1820-32. 10.1002\/hep.23594","journal-title":"Hepatology"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Zheng Y","year":"2018","unstructured":"Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018, 14:88-98. 10.1038\/nrendo.2017.151","journal-title":"Nat Rev Endocrinol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella ME","year":"2015","unstructured":"Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015, 313:2263-73. 10.1001\/jama.2015.5370","journal-title":"JAMA"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001680","article-title":"Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"Musso G","year":"2014","unstructured":"Musso G, Gambino R, Tabibian JH, et al.. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014, 11:e1001680. 10.1371\/journal.pmed.1001680","journal-title":"PLoS Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13338","article-title":"COVID-19 and non-alcoholic fatty liver disease: two intersecting pandemics","volume":"50","author":"Portincasa P","year":"2020","unstructured":"Portincasa P, Krawczyk M, Smyk W, Lammert F, Di Ciaula A. COVID-19 and non-alcoholic fatty liver disease: two intersecting pandemics. Eur J Clin Invest. 2020, 50:e13338. 10.1111\/eci.13338","journal-title":"Eur J Clin Invest"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v6.i5.274","article-title":"Gender and racial differences in nonalcoholic fatty liver disease","volume":"6","author":"Pan JJ","year":"2014","unstructured":"Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol. 2014, 6:274-83. 10.4254\/wjh.v6.i5.274","journal-title":"World J Hepatol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2013.193","article-title":"Developmental origins of nonalcoholic fatty liver disease","volume":"75","author":"Brumbaugh DE","year":"2014","unstructured":"Brumbaugh DE, Friedman JE. Developmental origins of nonalcoholic fatty liver disease. Pediatr Res. 2014, 75:140-7. 10.1038\/pr.2013.193","journal-title":"Pediatr Res"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.01.012","article-title":"Epidemiology and natural history of non-alcoholic fatty liver disease","volume":"65","author":"Fazel Y","year":"2016","unstructured":"Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016, 65:1017-25. 10.1016\/j.metabol.2016.01.012","journal-title":"Metabolism"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kws448","article-title":"Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994","volume":"178","author":"Lazo M","year":"2013","unstructured":"Lazo M, Hernaez R, Eberhardt MS, et al.. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2013, 178:38-45. 10.1093\/aje\/kws448","journal-title":"Am J Epidemiol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.21037\/tgh.2019.09.08","article-title":"Epidemiology of non-alcoholic and alcoholic fatty liver diseases","volume":"5","author":"Mitra S","year":"2020","unstructured":"Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol. 2020, 5:16. 10.21037\/tgh.2019.09.08","journal-title":"Transl Gastroenterol Hepatol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.12.005","article-title":"The burden of liver disease in Europe: a review of available epidemiological data","volume":"58","author":"Blachier M","year":"2013","unstructured":"Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013, 58:593-608. 10.1016\/j.jhep.2012.12.005","journal-title":"J Hepatol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.34","article-title":"NAFLD in Asia--as common and important as in the West","volume":"10","author":"Farrell GC","year":"2013","unstructured":"Farrell GC, Wong VW, Chitturi S. NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013, 10:307-18. 10.1038\/nrgastro.2013.34","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1017\/gheg.2019.2","article-title":"Non-alcoholic fatty liver disease in Africa: a hidden danger","volume":"4","author":"Paruk IM","year":"2019","unstructured":"Paruk IM, Pirie FJ, Motala AA. Non-alcoholic fatty liver disease in Africa: a hidden danger. Glob Health Epidemiol Genom. 2019, 4:e3. 10.1017\/gheg.2019.2","journal-title":"Glob Health Epidemiol Genom"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1091978","article-title":"The epidemiology of nonalcoholic fatty liver disease: a global perspective","volume":"28","author":"Lazo M","year":"2008","unstructured":"Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008, 28:339-50. 10.1055\/s-0028-1091978","journal-title":"Semin Liver Dis"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1002\/cld.948","article-title":"Racial disparities in diagnosis and prognosis of nonalcoholic fatty liver disease","volume":"16","author":"Samji NS","year":"2020","unstructured":"Samji NS, Snell PD, Singal AK, Satapathy SK. Racial disparities in diagnosis and prognosis of nonalcoholic fatty liver disease. Clin Liver Dis (Hoboken). 2020, 16:66-72. 10.1002\/cld.948","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01718.x","article-title":"Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus","volume":"29","author":"Leite NC","year":"2009","unstructured":"Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009, 29:113-9. 10.1111\/j.1478-3231.2008.01718.x","journal-title":"Liver Int"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S67400","article-title":"Mechanism linking diabetes mellitus and obesity","volume":"7","author":"Al-Goblan AS","year":"2014","unstructured":"Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes Metab Syndr Obes. 2014, 7:587-91. 10.2147\/DMSO.S67400","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12016","article-title":"Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals","volume":"1281","author":"Masuoka HC","year":"2013","unstructured":"Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci. 2013, 1281:106-22. 10.1111\/nyas.12016","journal-title":"Ann N Y Acad Sci"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i10.3023","article-title":"Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease","volume":"22","author":"Motamed N","year":"2016","unstructured":"Motamed N, Sohrabi M, Ajdarkosh H, et al.. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease. World J Gastroenterol. 2016, 22:3023-30. 10.3748\/wjg.v22.i10.3023","journal-title":"World J Gastroenterol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3444","article-title":"Body mass index and risk of nonalcoholic fatty liver disease: two electronic health record prospective studies","volume":"101","author":"Loomis AK","year":"2016","unstructured":"Loomis AK, Kabadi S, Preiss D, et al.. Body mass index and risk of nonalcoholic fatty liver disease: two electronic health record prospective studies. J Clin Endocrinol Metab. 2016, 101:945-52. 10.1210\/jc.2015-3444","journal-title":"J Clin Endocrinol Metab"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i28.9338","article-title":"Role of diet and lifestyle changes in nonalcoholic fatty liver disease","volume":"20","author":"Nseir W","year":"2014","unstructured":"Nseir W, Hellou E, Assy N. Role of diet and lifestyle changes in nonalcoholic fatty liver disease. World J Gastroenterol. 2014, 20:9338-44. 10.3748\/wjg.v20.i28.9338","journal-title":"World J Gastroenterol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1007\/s00394-018-1711-4","article-title":"Association of sugar sweetened beverages consumption with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"58","author":"Asgari-Taee F","year":"2019","unstructured":"Asgari-Taee F, Zerafati-Shoae N, Dehghani M, Sadeghi M, Baradaran HR, Jazayeri S. Association of sugar sweetened beverages consumption with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Nutr. 2019, 58:1759-69. 10.1007\/s00394-018-1711-4","journal-title":"Eur J Nutr"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3713","article-title":"Nonalcoholic fatty liver disease in the Rotterdam Study: about muscle mass, sarcopenia, fat mass, and fat distribution","volume":"34","author":"Alferink LJM","year":"2019","unstructured":"Alferink LJM, Trajanoska K, Erler NS, et al.. Nonalcoholic fatty liver disease in the Rotterdam Study: about muscle mass, sarcopenia, fat mass, and fat distribution. J Bone Miner Res. 2019, 34:1254-63. 10.1002\/jbmr.3713","journal-title":"J Bone Miner Res"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.08.019","article-title":"Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis","volume":"66","author":"Koo BK","year":"2017","unstructured":"Koo BK, Kim D, Joo SK, et al.. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol. 2017, 66:123-31. 10.1016\/j.jhep.2016.08.019","journal-title":"J Hepatol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqaa134","article-title":"NAFLD and NASH in postmenopausal women: implications for diagnosis and treatment","volume":"161","author":"DiStefano JK","year":"2020","unstructured":"DiStefano JK. NAFLD and NASH in postmenopausal women: implications for diagnosis and treatment. Endocrinology. 2020, 161:bqaa134. 10.1210\/endocr\/bqaa134","journal-title":"Endocrinology"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0556-1","article-title":"NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk","volume":"34","author":"Ballestri S","year":"2017","unstructured":"Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther. 2017, 34:1291-326. 10.1007\/s12325-017-0556-1","journal-title":"Adv Ther"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.06.007","article-title":"Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Hossain N","year":"2009","unstructured":"Hossain N, Afendy A, Stepanova M, et al.. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009, 7:1224-9. 10.1016\/j.cgh.2009.06.007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1177\/0049475517742261","article-title":"Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"48","author":"Tasneem AA","year":"2018","unstructured":"Tasneem AA, Luck NH, Majid Z. Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). Trop Doct. 2018, 48:107-12. 10.1177\/0049475517742261","journal-title":"Trop Doct"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010040","article-title":"Sphingolipids in non-alcoholic fatty liver disease and hepatocellular carcinoma: ceramide turnover","volume":"21","author":"Simon J","year":"2019","unstructured":"Simon J, Ouro A, Ala-Ibanibo L, Presa N, Delgado TC, Mart\u00ednez-Chantar ML. Sphingolipids in non-alcoholic fatty liver disease and hepatocellular carcinoma: ceramide turnover. Int J Mol Sci. 2019, 21:40. 10.3390\/ijms21010040","journal-title":"Int J Mol Sci"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.05.078","article-title":"Non-alcoholic fatty liver disease: insights from sphingolipidomics","volume":"504","author":"Montefusco DJ","year":"2018","unstructured":"Montefusco DJ, Allegood JC, Spiegel S, Cowart LA. Non-alcoholic fatty liver disease: insights from sphingolipidomics. Biochem Biophys Res Commun. 2018, 504:608-16. 10.1016\/j.bbrc.2018.05.078","journal-title":"Biochem Biophys Res Commun"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12456","article-title":"Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients","volume":"45","author":"Seko Y","year":"2015","unstructured":"Seko Y, Sumida Y, Tanaka S, et al.. Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res. 2015, 45:E53-61. 10.1111\/hepr.12456","journal-title":"Hepatol Res"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.603926","article-title":"Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments","volume":"11","author":"Peng C","year":"2020","unstructured":"Peng C, Stewart AG, Woodman OL, Ritchie RH, Qin CX. Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments. Front Pharmacol. 2020, 11:603926. 10.3389\/fphar.2020.603926","journal-title":"Front Pharmacol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"McPherson S","year":"2015","unstructured":"McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015, 62:1148-55. 10.1016\/j.jhep.2014.11.034","journal-title":"J Hepatol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon G","year":"2011","unstructured":"Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011, 34:274-85. 10.1111\/j.1365-2036.2011.04724.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.019984","article-title":"Long term prognosis of fatty liver: risk of chronic liver disease and death","volume":"53","author":"Dam-Larsen S","year":"2004","unstructured":"Dam-Larsen S, Franzmann M, Andersen IB, et al.. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 2004, 53:750-5. 10.1136\/gut.2003.019984","journal-title":"Gut"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh S","year":"2015","unstructured":"Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015, 13:643-54. 10.1016\/j.cgh.2014.04.014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2016.0109","article-title":"Genetic predisposition in nonalcoholic fatty liver disease","volume":"23","author":"Sookoian S","year":"2017","unstructured":"Sookoian S, Pirola CJ. Genetic predisposition in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2017, 23:1-12. 10.3350\/cmh.2016.0109","journal-title":"Clin Mol Hepatol"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo S","year":"2008","unstructured":"Romeo S, Kozlitina J, Xing C, et al.. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008, 40:1461-5. 10.1038\/ng.257","journal-title":"Nat Genet"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24283","article-title":"Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease","volume":"53","author":"Sookoian S","year":"2011","unstructured":"Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011, 53:1883-94. 10.1002\/hep.24283","journal-title":"Hepatology"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.064501","article-title":"A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis","volume":"285","author":"He S","year":"2010","unstructured":"He S, McPhaul C, Li JZ, et al.. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2010, 285:6706-15. 10.1074\/jbc.M109.064501","journal-title":"J Biol Chem"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma","volume":"61","author":"Liu YL","year":"2014","unstructured":"Liu YL, Patman GL, Leathart JB, et al.. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol. 2014, 61:75-81. 10.1016\/j.jhep.2014.02.030","journal-title":"J Hepatol"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.045","article-title":"The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans","volume":"65","author":"Luukkonen PK","year":"2016","unstructured":"Luukkonen PK, Zhou Y, Hy\u00f6tyl\u00e4inen T, et al.. The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. J Hepatol. 2016, 65:1263-5. 10.1016\/j.jhep.2016.07.045","journal-title":"J Hepatol"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina RM","year":"2016","unstructured":"Mancina RM, Dongiovanni P, Petta S, et al.. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology. 2016, 150:1219-30.e6. 10.1053\/j.gastro.2016.01.032","journal-title":"Gastroenterology"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.08.027","article-title":"rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: a meta-analysis","volume":"74","author":"Teo K","year":"2021","unstructured":"Teo K, Abeysekera KW, Adams L, et al.. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: a meta-analysis. J Hepatol. 2021, 74:20-30. 10.1016\/j.jhep.2020.08.027","journal-title":"J Hepatol"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04991-0","article-title":"MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals","volume":"7","author":"Donati B","year":"2017","unstructured":"Donati B, Dongiovanni P, Romeo S, et al.. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Sci Rep. 2017, 7:4492. 10.1038\/s41598-017-04991-0","journal-title":"Sci Rep"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina J","year":"2014","unstructured":"Kozlitina J, Smagris E, Stender S, et al.. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014, 46:352-6. 10.1038\/ng.2901","journal-title":"Nat Genet"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5309","article-title":"TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease","volume":"5","author":"Liu YL","year":"2014","unstructured":"Liu YL, Reeves HL, Burt AD, et al.. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014, 5:4309. 10.1038\/ncomms5309","journal-title":"Nat Commun"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam M","year":"2018","unstructured":"Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 2018, 68:268-79. 10.1016\/j.jhep.2017.09.003","journal-title":"J Hepatol"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v12.i10.792","article-title":"PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease","volume":"12","author":"Lisboa QC","year":"2020","unstructured":"Lisboa QC, Nardelli MJ, Pereira PA, et al.. PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease. World J Hepatol. 2020, 12:792-806. 10.4254\/wjh.v12.i10.792","journal-title":"World J Hepatol"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1001324","article-title":"Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits","volume":"7","author":"Speliotes EK","year":"2011","unstructured":"Speliotes EK, Yerges-Armstrong LM, Wu J, et al.. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011, 7:e1001324. 10.1371\/journal.pgen.1001324","journal-title":"PLoS Genet"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn NS","year":"2018","unstructured":"Abul-Husn NS, Cheng X, Li AH, et al.. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med. 2018, 378:1096-106. 10.1056\/NEJMoa1712191","journal-title":"N Engl J Med"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.01.007","article-title":"IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease","volume":"56","author":"Petta S","year":"2012","unstructured":"Petta S, Grimaudo S, Camm\u00e0 C, et al.. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. J Hepatol. 2012, 56:1356-62. 10.1016\/j.jhep.2012.01.007","journal-title":"J Hepatol"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.05.029","article-title":"The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies","volume":"56","author":"Al-Serri A","year":"2012","unstructured":"Al-Serri A, Anstee QM, Valenti L, et al.. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol. 2012, 56:448-54. 10.1016\/j.jhep.2011.05.029","journal-title":"J Hepatol"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i43.4835","article-title":"Promoting genetics in non-alcoholic fatty liver disease: combined risk score through polymorphisms and clinical variables","volume":"24","author":"Vespasiani-Gentilucci U","year":"2018","unstructured":"Vespasiani-Gentilucci U, Gallo P, Dell'Unto C, Volpentesta M, Antonelli-Incalzi R, Picardi A. Promoting genetics in non-alcoholic fatty liver disease: combined risk score through polymorphisms and clinical variables. World J Gastroenterol. 2018, 24:4835-45. 10.3748\/wjg.v24.i43.4835","journal-title":"World J Gastroenterol"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco C","year":"2021","unstructured":"Bianco C, Jamialahmadi O, Pelusi S, et al.. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol. 2021, 74:775-82. 10.1016\/j.jhep.2020.11.024","journal-title":"J Hepatol"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2018.01.001","article-title":"Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population","volume":"104","author":"Larrieta-Carrasco E","year":"2018","unstructured":"Larrieta-Carrasco E, Flores YN, Mac\u00edas-Kauffer LR, et al.. Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population. Exp Mol Pathol. 2018, 104:50-8. 10.1016\/j.yexmp.2018.01.001","journal-title":"Exp Mol Pathol"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.023","article-title":"Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease","volume":"160","author":"Jamialahmadi O","year":"2021","unstructured":"Jamialahmadi O, Mancina RM, Ciociola E, et al.. Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease. Gastroenterology. 2021, 160:1634-46.e7. 10.1053\/j.gastro.2020.12.023","journal-title":"Gastroenterology"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2016.11.008","article-title":"Epigenetics in non-alcoholic fatty liver disease","volume":"54","author":"Lee J","year":"2017","unstructured":"Lee J, Kim Y, Friso S, Choi SW. Epigenetics in non-alcoholic fatty liver disease. Mol Aspects Med. 2017, 54:78-88. 10.1016\/j.mam.2016.11.008","journal-title":"Mol Aspects Med"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.02.049","article-title":"Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease","volume":"63","author":"Kitamoto T","year":"2015","unstructured":"Kitamoto T, Kitamoto A, Ogawa Y, et al.. Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease. J Hepatol. 2015, 63:494-502. 10.1016\/j.jhep.2015.02.049","journal-title":"J Hepatol"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01129-y","article-title":"Differential DNA methylation and changing cell-type proportions as fibrotic stage progresses in NAFLD","volume":"13","author":"Johnson ND","year":"2021","unstructured":"Johnson ND, Wu X, Still CD, et al.. Differential DNA methylation and changing cell-type proportions as fibrotic stage progresses in NAFLD. Clin Epigenetics. 2021, 13:152. 10.1186\/s13148-021-01129-y","journal-title":"Clin Epigenetics"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302962","article-title":"Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease","volume":"62","author":"Pirola CJ","year":"2013","unstructured":"Pirola CJ, Gianotti TF, Burgue\u00f1o AL, et al.. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut. 2013, 62:1356-63. 10.1136\/gutjnl-2012-302962","journal-title":"Gut"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061355","article-title":"Epigenetic regulation of peroxisome proliferator-activated receptor gamma mediates high-fat diet-induced non-alcoholic fatty liver disease","volume":"10","author":"Hajri T","year":"2021","unstructured":"Hajri T, Zaiou M, Fungwe TV, Ouguerram K, Besong S. Epigenetic regulation of peroxisome proliferator-activated receptor gamma mediates high-fat diet-induced non-alcoholic fatty liver disease. Cells. 2021, 10:1355. 10.3390\/cells10061355","journal-title":"Cells"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00665-15","article-title":"Lysine acetylation of CREBH regulates fasting-induced hepatic lipid metabolism","volume":"35","author":"Kim H","year":"2015","unstructured":"Kim H, Mendez R, Chen X, Fang D, Zhang K. Lysine acetylation of CREBH regulates fasting-induced hepatic lipid metabolism. Mol Cell Biol. 2015, 35:4121-34. 10.1128\/MCB.00665-15","journal-title":"Mol Cell Biol"},{"key":"ref110","article-title":"SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress","volume":"16","author":"Kobayashi Y","year":"2005","unstructured":"Kobayashi Y, Furukawa-Hibi Y, Chen C, Horio Y, Isobe K, Ikeda K, Motoyama N. SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. Int J Mol Med. 2005, 16:237-43.","journal-title":"Int J Mol Med"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0465-x","article-title":"Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients","volume":"49","author":"Mariani S","year":"2015","unstructured":"Mariani S, Fiore D, Basciani S, et al.. Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients. Endocrine. 2015, 49:711-6. 10.1007\/s12020-014-0465-x","journal-title":"Endocrine"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119997","article-title":"The role of sirtuin 2 in sustaining functional integrity of the liver","volume":"285","author":"Park S","year":"2021","unstructured":"Park S, Chung MJ, Son JY, et al.. The role of sirtuin 2 in sustaining functional integrity of the liver. Life Sci. 2021, 285:119997. 10.1016\/j.lfs.2021.119997","journal-title":"Life Sci"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22569","article-title":"Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression","volume":"48","author":"Cheung O","year":"2008","unstructured":"Cheung O, Puri P, Eicken C, et al.. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology. 2008, 48:1810-20. 10.1002\/hep.22569","journal-title":"Hepatology"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i44.9844","article-title":"Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population","volume":"22","author":"Liu XL","year":"2016","unstructured":"Liu XL, Pan Q, Zhang RN, et al.. Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population. World J Gastroenterol. 2016, 22:9844-52. 10.3748\/wjg.v22.i44.9844","journal-title":"World J Gastroenterol"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105192","article-title":"A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease","volume":"9","author":"Tan Y","year":"2014","unstructured":"Tan Y, Ge G, Pan T, Wen D, Gan J. A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS One. 2014, 9:e105192. 10.1371\/journal.pone.0105192","journal-title":"PLoS One"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.736677","article-title":"Analysis of miRNAs profiles in serum of patients with steatosis and steatohepatitis","volume":"9","author":"Vulf M","year":"2021","unstructured":"Vulf M, Shunkina D, Komar A, et al.. Analysis of miRNAs profiles in serum of patients with steatosis and steatohepatitis. Front Cell Dev Biol. 2021, 9:736677. 10.3389\/fcell.2021.736677","journal-title":"Front Cell Dev Biol"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1971610","article-title":"The essence of senescence","volume":"24","author":"Kuilman T","year":"2010","unstructured":"Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev. 2010, 24:2463-79. 10.1101\/gad.1971610","journal-title":"Genes Dev"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100301","article-title":"Evaluating causality of cellular senescence in non-alcoholic fatty liver disease","volume":"3","author":"Meijnikman AS","year":"2021","unstructured":"Meijnikman AS, Herrema H, Scheithauer TP, Kroon J, Nieuwdorp M, Groen AK. Evaluating causality of cellular senescence in non-alcoholic fatty liver disease. JHEP Rep. 2021, 3:100301. 10.1016\/j.jhepr.2021.100301","journal-title":"JHEP Rep"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1038\/msb.2010.5","article-title":"Feedback between p21 and reactive oxygen production is necessary for cell senescence","volume":"6","author":"Passos JF","year":"2010","unstructured":"Passos JF, Nelson G, Wang C, et al.. Feedback between p21 and reactive oxygen production is necessary for cell senescence. Mol Syst Biol. 2010, 6:347. 10.1038\/msb.2010.5","journal-title":"Mol Syst Biol"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0050110","article-title":"Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence","volume":"5","author":"Passos JF","year":"2007","unstructured":"Passos JF, Saretzki G, Ahmed S, et al.. Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. PLoS Biol. 2007, 5:e110. 10.1371\/journal.pbio.0050110","journal-title":"PLoS Biol"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.23256","article-title":"Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities","volume":"120","author":"Sanyal AJ","year":"2001","unstructured":"Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al.. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001, 120:1183-92. 10.1053\/gast.2001.23256","journal-title":"Gastroenterology"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2005.10.004","article-title":"Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it","volume":"6","author":"Begriche K","year":"2006","unstructured":"Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006, 6:1-28. 10.1016\/j.mito.2005.10.004","journal-title":"Mitochondrion"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(98)70590-6","article-title":"Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes","volume":"114","author":"Berson A","year":"1998","unstructured":"Berson A, De Beco V, Lett\u00e9ron P, et al.. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology. 1998, 114:764-74. 10.1016\/s0016-5085(98)70590-6","journal-title":"Gastroenterology"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.921887","article-title":"The p66shc-mediated regulation of hepatocyte senescence influences hepatic steatosis in nonalcoholic fatty liver disease","volume":"26","author":"Zhang J","year":"2020","unstructured":"Zhang J, Li Y, Wang B, Luo Y, Shi J, Zhao B. The p66shc-mediated regulation of hepatocyte senescence influences hepatic steatosis in nonalcoholic fatty liver disease. Med Sci Monit. 2020, 26:e921887. 10.12659\/MSM.921887","journal-title":"Med Sci Monit"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15691","article-title":"Cellular senescence drives age-dependent hepatic steatosis","volume":"8","author":"Ogrodnik M","year":"2017","unstructured":"Ogrodnik M, Miwa S, Tchkonia T, et al.. Cellular senescence drives age-dependent hepatic steatosis. Nat Commun. 2017, 8:15691. 10.1038\/ncomms15691","journal-title":"Nat Commun"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0218-8","article-title":"Detection of DNA damage response in nonalcoholic fatty liver disease via p53-binding protein 1 nuclear expression","volume":"32","author":"Akazawa Y","year":"2019","unstructured":"Akazawa Y, Nakashima R, Matsuda K, et al.. Detection of DNA damage response in nonalcoholic fatty liver disease via p53-binding protein 1 nuclear expression. Mod Pathol. 2019, 32:997-1007. 10.1038\/s41379-019-0218-8","journal-title":"Mod Pathol"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2020.07.003","article-title":"Study of cellular senescence and vitamin D deficiency in nonalcoholic fatty liver disease and the potential protective effect of vitamin D supplementation","volume":"11","author":"Al-Ghamdi HA","year":"2021","unstructured":"Al-Ghamdi HA, Al Fayez FF, Bima AI, Khawaji TM, Elsamanoudy AZ. Study of cellular senescence and vitamin D deficiency in nonalcoholic fatty liver disease and the potential protective effect of vitamin D supplementation. J Clin Exp Hepatol. 2021, 11:219-26. 10.1016\/j.jceh.2020.07.003","journal-title":"J Clin Exp Hepatol"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1016\/j.fob.2014.05.003","article-title":"Senescence marker protein-30\/superoxide dismutase 1 double knockout mice exhibit increased oxidative stress and hepatic steatosis","volume":"4","author":"Kondo Y","year":"2014","unstructured":"Kondo Y, Masutomi H, Noda Y, et al.. Senescence marker protein-30\/superoxide dismutase 1 double knockout mice exhibit increased oxidative stress and hepatic steatosis. FEBS Open Bio. 2014, 4:522-32. 10.1016\/j.fob.2014.05.003","journal-title":"FEBS Open Bio"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147702","article-title":"Mitochondria matter: systemic aspects of nonalcoholic fatty liver disease (NAFLD) and diagnostic assessment of liver function by stable isotope dynamic breath tests","volume":"22","author":"Di Ciaula A","year":"2021","unstructured":"Di Ciaula A, Calamita G, Shanmugam H, et al.. Mitochondria matter: systemic aspects of nonalcoholic fatty liver disease (NAFLD) and diagnostic assessment of liver function by stable isotope dynamic breath tests. Int J Mol Sci. 2021, 22:7702. 10.3390\/ijms22147702","journal-title":"Int J Mol Sci"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094459","article-title":"Mitochondrial mutations and genetic factors determining NAFLD risk","volume":"22","author":"Dabravolski SA","year":"2021","unstructured":"Dabravolski SA, Bezsonov EE, Baig MS, Popkova TV, Nedosugova LV, Starodubova AV, Orekhov AN. Mitochondrial mutations and genetic factors determining NAFLD risk. Int J Mol Sci. 2021, 22:4459. 10.3390\/ijms22094459","journal-title":"Int J Mol Sci"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.04.008","article-title":"A position statement on NAFLD\/NASH based on the EASL 2009 special conference","volume":"53","author":"Ratziu V","year":"2010","unstructured":"Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD\/NASH based on the EASL 2009 special conference. J Hepatol. 2010, 53:372-84. 10.1016\/j.jhep.2010.04.008","journal-title":"J Hepatol"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo P","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, et al.. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015, 149:389-97.e10. 10.1053\/j.gastro.2015.04.043","journal-title":"Gastroenterology"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24491","article-title":"The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study","volume":"54","author":"Bhala N","year":"2011","unstructured":"Bhala N, Angulo P, van der Poorten D, et al.. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011, 54:1208-16. 10.1002\/hep.24491","journal-title":"Hepatology"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-019-0681-x","article-title":"The epidemiology of hepatocellular carcinoma in the USA","volume":"21","author":"Kim HS","year":"2019","unstructured":"Kim HS, El-Serag HB. The epidemiology of hepatocellular carcinoma in the USA. Curr Gastroenterol Rep. 2019, 21:17. 10.1007\/s11894-019-0681-x","journal-title":"Curr Gastroenterol Rep"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31014","article-title":"Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease","volume":"71","author":"Kanwal F","year":"2020","unstructured":"Kanwal F, Kramer JR, Li L, et al.. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology. 2020, 71:808-19. 10.1002\/hep.31014","journal-title":"Hepatology"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-017-4684-x","article-title":"Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes","volume":"62","author":"Cholankeril G","year":"2017","unstructured":"Cholankeril G, Wong RJ, Hu M, et al.. Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes. Dig Dis Sci. 2017, 62:2915-22. 10.1007\/s10620-017-4684-x","journal-title":"Dig Dis Sci"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"Younossi ZM","year":"2019","unstructured":"Younossi ZM. Non-alcoholic fatty liver disease - a global public health perspective. J Hepatol. 2019, 70:531-44. 10.1016\/j.jhep.2018.10.033","journal-title":"J Hepatol"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams LA","year":"2017","unstructured":"Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017, 66:1138-53. 10.1136\/gutjnl-2017-313884","journal-title":"Gut"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher G","year":"2016","unstructured":"Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016, 65:589-600. 10.1016\/j.jhep.2016.05.013","journal-title":"J Hepatol"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.07.052","article-title":"A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?","volume":"230","author":"Oni ET","year":"2013","unstructured":"Oni ET, Agatston AS, Blaha MJ, et al.. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?. Atherosclerosis. 2013, 230:258-67. 10.1016\/j.atherosclerosis.2013.07.052","journal-title":"Atherosclerosis"},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1562944","article-title":"Systemic complications of nonalcoholic fatty liver disease: when the liver is not an innocent bystander","volume":"35","author":"Vanni E","year":"2015","unstructured":"Vanni E, Marengo A, Mezzabotta L, Bugianesi E. Systemic complications of nonalcoholic fatty liver disease: when the liver is not an innocent bystander. Semin Liver Dis. 2015, 35:236-49. 10.1055\/s-0035-1562944","journal-title":"Semin Liver Dis"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.05.019","article-title":"CKD and nonalcoholic fatty liver disease","volume":"64","author":"Targher G","year":"2014","unstructured":"Targher G, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. Am J Kidney Dis. 2014, 64:638-52. 10.1053\/j.ajkd.2014.05.019","journal-title":"Am J Kidney Dis"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i43.9488","article-title":"Nonalcoholic fatty liver disease - a multisystem disease?","volume":"22","author":"Mikolasevic I","year":"2016","unstructured":"Mikolasevic I, Milic S, Turk Wensveen T, et al.. Nonalcoholic fatty liver disease - a multisystem disease?. World J Gastroenterol. 2016, 22:9488-505. 10.3748\/wjg.v22.i43.9488","journal-title":"World J Gastroenterol"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2015.00001","article-title":"Management of moderate to severe psoriasis in patients with metabolic comorbidities","volume":"2","author":"Gisondi P","year":"2015","unstructured":"Gisondi P, Galvan A, Idolazzi L, Girolomoni G. Management of moderate to severe psoriasis in patients with metabolic comorbidities. Front Med (Lausanne). 2015, 2:1. 10.3389\/fmed.2015.00001","journal-title":"Front Med (Lausanne)"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)31616-3","article-title":"Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens","volume":"9","author":"Gutierrez-Grobe Y","year":"2010","unstructured":"Gutierrez-Grobe Y, Ponciano-Rodr\u00edguez G, Ramos MH, Uribe M, M\u00e9ndez-S\u00e1nchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol. 2010, 9:402-9. 10.1016\/S1665-2681(19)31616-3","journal-title":"Ann Hepatol"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12020","article-title":"Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis","volume":"14","author":"Musso G","year":"2013","unstructured":"Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev. 2013, 14:417-31. 10.1111\/obr.12020","journal-title":"Obes Rev"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i26.8341","article-title":"Modern approach to the clinical management of non-alcoholic fatty liver disease","volume":"20","author":"Del Ben M","year":"2014","unstructured":"Del Ben M, Polimeni L, Baratta F, Pastori D, Loffredo L, Angelico F. Modern approach to the clinical management of non-alcoholic fatty liver disease. World J Gastroenterol. 2014, 20:8341-50. 10.3748\/wjg.v20.i26.8341","journal-title":"World J Gastroenterol"},{"key":"ref148","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22964","article-title":"A fad too far? Dietary strategies for the prevention and treatment of NAFLD","volume":"28","author":"Moore MP","year":"2020","unstructured":"Moore MP, Cunningham RP, Dashek RJ, Mucinski JM, Rector RS. A fad too far? Dietary strategies for the prevention and treatment of NAFLD. Obesity (Silver Spring). 2020, 28:1843-52. 10.1002\/oby.22964","journal-title":"Obesity (Silver Spring)"},{"key":"ref149","doi-asserted-by":"publisher","DOI":"10.3390\/diseases6040086","article-title":"The role of vitamin E in the treatment of NAFLD","volume":"6","author":"Perumpail BJ","year":"2018","unstructured":"Perumpail BJ, Li AA, John N, et al.. The role of vitamin E in the treatment of NAFLD. Diseases. 2018, 6:86. 10.3390\/diseases6040086","journal-title":"Diseases"},{"key":"ref150","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.08699.x","article-title":"Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis","volume":"98","author":"Harrison SA","year":"2003","unstructured":"Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003, 98:2485-90. 10.1111\/j.1572-0241.2003.08699.x","journal-title":"Am J Gastroenterol"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1437","article-title":"Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)","volume":"306","author":"Klein EA","year":"2011","unstructured":"Klein EA, Thompson IM Jr, Tangen CM, et al.. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011, 306:1549-56. 10.1001\/jama.2011.1437","journal-title":"JAMA"},{"key":"ref152","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-012-2118-3","article-title":"Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies","volume":"57","author":"Nseir W","year":"2012","unstructured":"Nseir W, Mograbi J, Ghali M. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci. 2012, 57:1773-81. 10.1007\/s10620-012-2118-3","journal-title":"Dig Dis Sci"},{"key":"ref153","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.11.014","article-title":"Liver transplantation for nonalcoholic steatohepatitis","volume":"12","author":"Asrani SK","year":"2014","unstructured":"Asrani SK. Liver transplantation for nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2014, 12:403-4. 10.1016\/j.cgh.2013.11.014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref154","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100192","article-title":"NAFLD and liver transplantation: disease burden, current management and future challenges","volume":"2","author":"Burra P","year":"2020","unstructured":"Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: disease burden, current management and future challenges. JHEP Rep. 2020, 2:100192. 10.1016\/j.jhepr.2020.100192","journal-title":"JHEP Rep"},{"key":"ref155","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v11.i2.138","article-title":"Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects","volume":"11","author":"Laursen TL","year":"2019","unstructured":"Laursen TL, Hagemann CA, Wei C, Kazankov K, Thomsen KL, Knop FK, Gr\u00f8nb\u00e6k H. Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. World J Hepatol. 2019, 11:138-49. 10.4254\/wjh.v11.i2.138","journal-title":"World J Hepatol"},{"key":"ref156","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"13","author":"Armstrong MJ","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al.. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016, 13:679-90. 10.1016\/S0140-6736(15)00803-X","journal-title":"Lancet"},{"key":"ref157","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i32.3663","article-title":"Betaine and nonalcoholic steatohepatitis: back to the future?","volume":"17","author":"Mukherjee S","year":"2011","unstructured":"Mukherjee S. Betaine and nonalcoholic steatohepatitis: back to the future?. World J Gastroenterol. 2011, 17:3663-4. 10.3748\/wjg.v17.i32.3663","journal-title":"World J Gastroenterol"},{"key":"ref158","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2019.105922","article-title":"Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA phase 3 study design","volume":"89","author":"Anstee QM","year":"2020","unstructured":"Anstee QM, Neuschwander-Tetri BA, Wong VW, et al.. Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA phase 3 study design. Contemp Clin Trials. 2020, 89:105922. 10.1016\/j.cct.2019.105922","journal-title":"Contemp Clin Trials"},{"key":"ref159","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0297-5","article-title":"No anti-fibrotic effect of selonsertib in NASH","volume":"17","author":"Dickson I","year":"2020","unstructured":"Dickson I. No anti-fibrotic effect of selonsertib in NASH. Nat Rev Gastroenterol Hepatol. 2020, 17:260. 10.1038\/s41575-020-0297-5","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref160","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis","volume":"155","author":"Harrison SA","year":"2018","unstructured":"Harrison SA, Abdelmalek MF, Caldwell S, et al.. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology. 2018, 155:1140-53. 10.1053\/j.gastro.2018.07.006","journal-title":"Gastroenterology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/79401-factors-that-predict-the-progression-of-non-alcoholic-fatty-liver-disease-nafld","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:31:13Z","timestamp":1707507073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/79401-factors-that-predict-the-progression-of-non-alcoholic-fatty-liver-disease-nafld"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,28]]},"references-count":160,"URL":"https:\/\/doi.org\/10.7759\/cureus.20776","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,28]]}}}